Double-Blind Trial with Sulfamethoxazole plus Trimethoprim (Bactrim) versus Demethyl-chlortetracycline (Ledermycin) in Chronic Respiratory Tract Infections

Publisher Website
Google Scholar
Abstract
In a double-blind trial on a total of 39 patients suffering from acute exacerbations of a chronic respiratory tract infection, we tested the effectiveness of the antibacterial combination chemotherapeutic drug Bactrim® (active agents: 400 mg sulfamethoxazole + 80 mg trimethoprim per tablet) against that of our standard antibiotic demethyl-chlortetracycline (Ledermycin®). The duration of treatment was 14 days in all the cases. The success criteria, beside the clinical findings, were the results of laboratory and bacteriological investigations, and daily assessments of the sputum in respect of appearance and quantity. Despite the fact that the randomization procedure accidentally resulted in the assignment of a larger proportion of the more severe cases to the Bactrim group than to the tetracycline group, the results of therapy with Bactrim were somewhat better than those with the control preparation. Almost all the pathogens isolated from the sputum of the patients were Bactrim-sensitive; no development of resistance was observed. Both test preparations were well tolerated.

This publication has 0 references indexed in Scilit: